Evidence map›Paper›PMID 30753210›Full record

ArticlePloS one2019

Utility of MALDI-TOF MS as a new tool for Streptococcus pneumoniae serotyping.

María Ercibengoa, Marta Alonso, Diego Vicente, Maria Morales, Ernesto Garcia, Jose María Marimón

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. ExploringJournal of mass spectrometry and advances in the clinical lab · 2023
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

María ErcibengoaHospital Universitario Donostia-Instituto de Investigación Sanitaria Biodonostia, San Sebastián, Spain.ORCID 0000-0001-9152-6590
Marta AlonsoHospital Universitario Donostia-Instituto de Investigación Sanitaria Biodonostia, San Sebastián, Spain.
Diego VicenteHospital Universitario Donostia-Instituto de Investigación Sanitaria Biodonostia, San Sebastián, Spain.
Maria MoralesCIBER de Enfermedades Respiratorias-CIBERES, Madrid, Spain.
Ernesto GarciaCIBER de Enfermedades Respiratorias-CIBERES, Madrid, Spain.
Jose María MarimónHospital Universitario Donostia-Instituto de Investigación Sanitaria Biodonostia, San Sebastián, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESConsejo Superior de Investigaciones Científicas · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nowadays, more than 95 different Streptococcus pneumoniae serotypes are known, being less than one third responsible for the majority of severe pneumococcal infections. After the introduction of conjugate vaccines, a change in the epidemiology of the serotypes causing invasive pneumococcal disease has been observed making the surveillance of circulating serotypes especially relevant. Some recent studies have used matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) technology to identify the most frequent pneumococcal serotypes that cause invasive disease. The objectives of this study were to evaluate the efficacy of previously described discriminatory peaks determined by MALDI-TOF MS for the identification of serotypes 6B, 19F, 19A and 35B using reference and clinical isolates and to try to identify other discriminatory peaks for serotypes 11A, 19F and 19A using transformed pneumococcal strains. Most of the proposed peaks defined in the literature for the identification of serotypes 6B, 19F, 19A, 35B were not found in the spectra of the 10 reference isolates nor in those of the 60 clinical isolates tested corresponding to these four serotypes. The analysis and comparison of the mass spectra of genetically modified pneumococci (transformed strains) did not allow the establishment of new discriminatory peaks for serotypes 11A, 19F, and 19A. MALDI-TOF MS in the usual range of 2,000 to 20,000 m/z did not prove to be a valid technique for direct S. pneumoniae serotyping.

Indexed as

Bacterial Typing TechniquesHumansMolecular TypingPneumococcal InfectionsPneumococcal VaccinesSerotypingSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStreptococcus pneumoniaeVaccines, ConjugatePneumococcal VaccinesVaccines, Conjugate

Identifiers

PMID30753210
PMCPMC6372175
OpenAlexW2914376563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.